Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) announced that it is currently advancing two Phase III clinical trials for Anguladivir granules in treating children aged 2–11 with uncomplicated influenza A, as well as Anguladivir tablets for adolescents aged 12–17 with uncomplicated influenza A. Additionally, Phase III trials are underway for RAY1225 injection in treating obesity/overweight patients and two Phase III trials for RAY1225 injection in type 2 diabetes patients. The progress of clinical trials, review and approval outcomes, and future market competition for these innovative drug R&D projects remain uncertain. The approval timeline for market launch, as well as post-approval production and sales performance, are also subject to unpredictability.

Anguladivir tablets, a small-molecule innovative drug for treating uncomplicated influenza A in adults, have already received approval from China's National Medical Products Administration (NMPA). It is the world's first influenza RNA polymerase PB2 protein inhibitor. However, due to the inherent characteristics of the pharmaceutical industry, commercialization post-approval may be influenced by market conditions, policy shifts, and environmental changes. Factors such as the prevalence of preventive vaccines, the approval of competing treatments, and post-launch market promotion efforts could further impact the commercial success and sales performance of Anguladivir tablets.